Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : RVNC save search
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -1.06%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 6.13%
H: 1.54%
C: -3.04%
daxxify fda treatment injection
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: 0.44%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.48%
H: 4.73%
C: 2.5%
daxxify treatment meeting association injection
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2022-10-20 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.11%
H: 1.17%
C: -0.53%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -0.04%
H: 3.56%
C: -1.55%
treatment application license injection
Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)
Published: 2022-09-15 (Crawled : 22:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.11%
H: 3.08%
C: 1.38%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: -3.3%
treatment parkinson trial injection international
Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
Published: 2021-09-01 (Crawled : 13:15) - biospace.com/
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -0.15%
H: 1.57%
C: 1.31%
treatment injection results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.